Genetics of Candida albicans, a diploid human fungal pathogen ,
, Annu Rev Genet, vol.41, pp.193-211, 2007.
Invasive Candidiasis, N Engl J Med, vol.373, pp.1445-56, 2015. ,
ESCMID* guideline for the diagnosis and 380 management of Candida diseases 2012: non-neutropenic adult patients, Clin Microbiol, p.381 ,
, Infect Off Publ Eur Soc Clin Microbiol Infect Dis, vol.18, pp.19-37, 2012.
Clinical Practice Guideline for the Management 383 of Candidiasis: 2016 Update by the Infectious Diseases Society of America, Clin Infect Dis Off ,
, Publ Infect Dis Soc Am, vol.62, pp.1-50, 2016.
Positions and Numbers of FKS Mutations in ,
, Candida albicans Selectively Influence In Vitro and In Vivo Susceptibilities to Echinocandin
, Antimicrob Agents Chemother, vol.58, pp.3626-3661, 2014.
Invasive Candidiasis in Critically Ill Patients: A 389 ,
, Prospective Cohort Study in Two Tertiary Care Centers, J Intensive Care Med, vol.2018, p.390
Worldwide emergence of resistance to 392 antifungal drugs challenges human health and food security, Science, vol.360, pp.739-781, 2018. ,
Echinocandin and triazole antifungal 394 susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 characterization of geographic and temporal trends of antifungal resistance, J Clin Microbiol, vol.397, pp.2571-81, 2013. ,
,
, Azole Antifungal Resistance in Candida albicans 399 and Emerging Non-albicans Candida Species, Front Microbiol, vol.7, 2017.
Assessing resistance to the echinocandin antifungal drug 402 caspofungin in Candida albicans by profiling mutations in FKS1, Antimicrob Agents 403 Chemother, vol.50, pp.2058-63, 2006. ,
Distinct roles of Candida albicans drug resistance 405 transcription factors TAC1, MRR1, and UPC2 in virulence, Eukaryot Cell, vol.13, pp.127-169, 2014. ,
Resistance of Candida species to antifungal agents: molecular 407 mechanisms and clinical consequences, Lancet Infect Dis, vol.2, pp.73-85, 2002. ,
TAC1, transcriptional activator of CDR genes, is a 409 new transcription factor involved in the regulation of Candida albicans ABC transporters 410 CDR1 and CDR2, Eukaryot Cell, vol.3, pp.1639-52, 2004. ,
Molecular basis of antifungal drug resistance in 412 yeasts, Int J Antimicrob Agents, vol.50, pp.599-606, 2017. ,
Role of Candida albicans transcription factor Upc2p in 414 drug resistance and sterol metabolism, Eukaryot Cell, vol.3, pp.1391-1398, 2004. ,
cis-Acting elements within the Candida albicans 416 ERG11 promoter mediate the azole response through transcription factor Upc2p, Eukaryot 417 Cell, vol.6, pp.450-60, 2007. ,
A CTG Clade Candida Yeast Genetically 566 Engineered for the Genotype-Phenotype Characterization of Azole Antifungal Resistance in ,
, Antimicrob Agents Chemother, vol.62, 2017.
A Candida albicans CRISPR system permits genetic 570 engineering of essential genes and gene families, Sci Adv, vol.1, p.1500248, 2015. ,